. Blood glucose levels ≥600 mg/dL correspond to C-peptide levels ≤150 ng/ml. NOD mice developed spontaneous diabetes, defined as a blood glucose of 200-250 mg/dL, and were treated with PPCA (either WEE1i + MDM2i or CHKi + MDM2i) or vehicle on days 1-3 after development, or were left untreated until blood glucose ≥600 mg/dL. C-peptide was quantified from serum samples by ELISA.
. PPCA decreases number of activated diabetogenic T cells displaying DNA damage markers. NOD mice were treated with WEE1i and MDM2i or vehicle days 1-3 after developing diabetes (BG=200-250mg/dL) and harvested on day 4. Lymphocytes isolated from spleen and pancreas were stained for γH2AX and phospho-p53 in naïve and activated T cells; representative flow cytometric analysis. Red: naïve (CD4+ FoxP3-CD62L+ CD44-tetramer+), blue: activated (CD4+ FoxP3-CD62L-CD44+ tetramer+). Figure 3 . PPCA does not affect memory T cells or recall responses. NOD mice were infected with LCMV (Armstrong, 2.5 x 10 5 pfu, administered i.p.) and treated with either WEE1i + MDM2i or vehicle on days 60-62, 67-69, and 74-76 post-infection. Mice were re-challenged with LCMV (Clone 13, 1.5 x 10 6 pfu, administered i.v.) on day 110 and harvested on day 115. Lymphocytes were isolated from the spleen and stained with LCMV GP 33-41 D b tetramer or restimulated with LCMV GP61 or GP33 peptides in the presence of Brefeldin A to assess cytokine production. (A) Schematic of experimental design with representative images. (B) Percentage of GP33 tetramer + CD8 + T cells. (C) Percentage of IFN-γ + CD4 + and CD8 + T cells after 5 hour stimulation with GP61 or GP33, respectively. (D) Percentage of TNFα + CD4 + and CD8 + T cells after 5 hour stimulation with GP61 or GP33, respectively. *P>0.05, **P>0.01. Figure 4 . PPCA decreases cells with DNA damage markers in activated diabetogenic cells, but not in naïve or regulatory cells. NOD mice were treated with WEE1i and MDM2i or vehicle days 1-3 after developing diabetes (BG=200-250mg/dL) and harvested on day 4. Lymphocytes isolated from spleen and pancreas were stained for γH2AX in naïve (CD4 + CD62L + ), effector (CD4+ CD44+ tetramer+) and regulatory (CD4 + FoxP3 + ) T cells; n=1-2 mice per group. Red: New onset diabetes, vehicle treated, blue: new onset diabetes, PPCA treated. *P>0.05, ****P>0.0001. Figure 5 . PPCA therapy requires intact Treg cell function. Depletion of Treg cells using cyclophosphamide (200 mg/kg) results in autoimmune diabetes within ~72 hours of treatment. 10 to 12-week-old NOD mice were treated with cyclophosphamide in order to induce diabetes, and were treated using the same treatment dosage and strategy as mice which developed diabetes spontaneously (BG≥200 mg/dL). Blue: PPCA treated, spontaneous onset, white: PPCA treated, cyclophosphamide induced; n=13-20 mice per group. ***P>0.001. Figure 6 Minimal gene expression differences in naïve T cells treated with PPCA or Vehicle control. Principal Component Analysis (PCA) showing variance between activated (CD44 + ) CD4 + (Tet + or Tet -) T Cells PPCA-and Vehicle-treated (Red) versus Naïve (CD4+CD44-/lo) from PPCA-and Vehicle-Treated (Blue) based upon differentially expressed genes (fold-change > 2.0, pvalue < 0.05) between PPCA-treated and Vehicle-treated mice. Figure 7 . Spleen and pancreas show similar levels of cell cycle and DNA damage markers. NOD mice were treated with WEE1i and MDM2i or vehicle days 1-3 after developing diabetes (BG=200-250mg/dL) and harvested on day 4. Lymphocytes isolated from spleen and pancreas were stained for γH2AX and Ki67 in effector (CD4+ CD44+ tetramer+) T cells; n=1-7 mice per group.
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